Pages with the fewest revisions

Jump to navigation Jump to search

Showing below up to 500 results in range #101 to #600.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. ICRP Publication 149‏‎ (1 revision)
  2. International Commission on Radiological Protection‏‎ (1 revision)
  3. ICRP Publication 23‏‎ (1 revision)
  4. DRL quantity‏‎ (1 revision)
  5. Lag‏‎ (1 revision)
  6. ICRP Publication 30 (Supplement to Part 1)‏‎ (1 revision)
  7. Designated area‏‎ (1 revision)
  8. Teratocarcinoma‏‎ (1 revision)
  9. Low dose‏‎ (1 revision)
  10. ICRP Publication 44‏‎ (1 revision)
  11. Distribution coefficient‏‎ (1 revision)
  12. ICRP Publication 59‏‎ (1 revision)
  13. ICRP Publication 73‏‎ (1 revision)
  14. ICRP Publication 88‏‎ (1 revision)
  15. Epigenetic effects‏‎ (1 revision)
  16. 1928 Recommendations‏‎ (1 revision)
  17. Potentially lethal damage repair‏‎ (1 revision)
  18. Additive risk projection model‏‎ (1 revision)
  19. ICRP Publication 106‏‎ (1 revision)
  20. Relative risk‏‎ (1 revision)
  21. ICRP Publication 120‏‎ (1 revision)
  22. Carers and comforters‏‎ (1 revision)
  23. ICRP Publication 135‏‎ (1 revision)
  24. ICRP Publication 15‏‎ (1 revision)
  25. Source region‏‎ (1 revision)
  26. ICRP Publication 24‏‎ (1 revision)
  27. Late normal tissue responses‏‎ (1 revision)
  28. ICRP Publication 30 (Supplement to Part 2)‏‎ (1 revision)
  29. Detector quantum efficiency‏‎ (1 revision)
  30. ICRP Publication 45‏‎ (1 revision)
  31. ICRP Publication 6‏‎ (1 revision)
  32. ICRP Publication 74‏‎ (1 revision)
  33. Α/β value‏‎ (1 revision)
  34. Oncogene‏‎ (1 revision)
  35. ICRP Publication 89‏‎ (1 revision)
  36. Exogenous excretion‏‎ (1 revision)
  37. 1931 Recommendations‏‎ (1 revision)
  38. Adenoma‏‎ (1 revision)
  39. ICRP Publication 107‏‎ (1 revision)
  40. Relative survival‏‎ (1 revision)
  41. ICRP Publication 121‏‎ (1 revision)
  42. Case–control study‏‎ (1 revision)
  43. ICRP Publication 136‏‎ (1 revision)
  44. Collective dose‏‎ (1 revision)
  45. Severe deterministic injury‏‎ (1 revision)
  46. ICRP Publication 150‏‎ (1 revision)
  47. Intervention‏‎ (1 revision)
  48. ICRP Publication 25‏‎ (1 revision)
  49. Sublethal damage repair‏‎ (1 revision)
  50. ICRP Publication 31‏‎ (1 revision)
  51. Deterministic effect‏‎ (1 revision)
  52. ICRP Publication 46‏‎ (1 revision)
  53. Transfer of risk‏‎ (1 revision)
  54. Molecular imaging‏‎ (1 revision)
  55. ICRP Publication 60‏‎ (1 revision)
  56. Dose modifying factor‏‎ (1 revision)
  57. Noise‏‎ (1 revision)
  58. ICRP Publication 75‏‎ (1 revision)
  59. ΓH2AX foci‏‎ (1 revision)
  60. Operating management‏‎ (1 revision)
  61. ICRP Publication 9‏‎ (1 revision)
  62. Pencil beam‏‎ (1 revision)
  63. 1934 Recommendations‏‎ (1 revision)
  64. Practice‏‎ (1 revision)
  65. Access control‏‎ (1 revision)
  66. General Information: Radon‏‎ (1 revision - redirect page)
  67. ICRP Publication 108‏‎ (1 revision)
  68. Brachytherapy‏‎ (1 revision)
  69. ICRP Publication 122‏‎ (1 revision)
  70. Risk model‏‎ (1 revision)
  71. ICRP Publication 137‏‎ (1 revision)
  72. Sheltering‏‎ (1 revision)
  73. Induced genomic instability‏‎ (1 revision)
  74. ICRP Publication 151‏‎ (1 revision)
  75. ICRP Publication 26‏‎ (1 revision)
  76. DS86‏‎ (1 revision)
  77. Licensee‏‎ (1 revision)
  78. ICRP Publication 32‏‎ (1 revision)
  79. Thermodynamic diameter‏‎ (1 revision)
  80. Low linear energy transfer radiation‏‎ (1 revision)
  81. ICRP Publication 47‏‎ (1 revision)
  82. ICRP Publication 61‏‎ (1 revision)
  83. Nominal risk coefficient‏‎ (1 revision)
  84. ICRP Publication 76‏‎ (1 revision)
  85. Equilibrium equivalent concentration‏‎ (1 revision)
  86. Expanded radiation field‏‎ (1 revision)
  87. 1937 Recommendations‏‎ (1 revision)
  88. Quality control testing‏‎ (1 revision)
  89. Adventitious source‏‎ (1 revision)
  90. Radioactive waste‏‎ (1 revision)
  91. Annual intake‏‎ (1 revision)
  92. ICRP Publication 109‏‎ (1 revision)
  93. ICRP Publication 123‏‎ (1 revision)
  94. Charged-particle equilibrium‏‎ (1 revision)
  95. ICRPædia Guide to Radiological Protection in Healthcare‏‎ (1 revision - redirect page)
  96. ICRP Publication 138‏‎ (1 revision)
  97. Collimation‏‎ (1 revision)
  98. Shielding‏‎ (1 revision)
  99. ICRP Publication 152‏‎ (1 revision)
  100. ICRP Publication 27‏‎ (1 revision)
  101. Superposition principle‏‎ (1 revision)
  102. Life Span Study‏‎ (1 revision)
  103. ICRP Publication 33‏‎ (1 revision)
  104. Detriment-adjusted risk‏‎ (1 revision)
  105. Thoracic airways‏‎ (1 revision)
  106. ICRP Publication 48‏‎ (1 revision)
  107. Dose-response function‏‎ (1 revision)
  108. Multifactorial diseases‏‎ (1 revision)
  109. ICRP Publication 62‏‎ (1 revision)
  110. Nominal value‏‎ (1 revision)
  111. ICRP Publication 77‏‎ (1 revision)
  112. Equilibrium factor‏‎ (1 revision)
  113. 1950 Recommendations‏‎ (1 revision)
  114. Backscatter factor‏‎ (1 revision)
  115. ICRP Publication 10A‏‎ (1 revision)
  116. ICRP Publication 124‏‎ (1 revision)
  117. ICRP Publication 139‏‎ (1 revision)
  118. ICRP Publication 153‏‎ (1 revision)
  119. ICRP Publication 28‏‎ (1 revision)
  120. Supervised area‏‎ (1 revision)
  121. ICRP Publication 34‏‎ (1 revision)
  122. Thoron progeny‏‎ (1 revision)
  123. ICRP Publication 49‏‎ (1 revision)
  124. Transgenerational effect‏‎ (1 revision)
  125. ICRP Publication 63‏‎ (1 revision)
  126. Non-homologous end joining‏‎ (1 revision)
  127. ICRP Publication 78‏‎ (1 revision)
  128. Elemental dose‏‎ (1 revision)
  129. Optimisation of protection‏‎ (1 revision)
  130. Exposed individuals‏‎ (1 revision)
  131. 1954 Recommendations‏‎ (1 revision)
  132. Quasi-threshold dose‏‎ (1 revision)
  133. Apoptosis‏‎ (1 revision)
  134. Radon progeny‏‎ (1 revision)
  135. Reference parameter value‏‎ (1 revision)
  136. ICRP Publication 11‏‎ (1 revision)
  137. ICRP Publication 125‏‎ (1 revision)
  138. ICRP Publication 14‏‎ (1 revision)
  139. Commissioning‏‎ (1 revision)
  140. Size-specific dose estimate‏‎ (1 revision)
  141. ICRP Publication 154‏‎ (1 revision)
  142. Cosmic radiation‏‎ (1 revision)
  143. Specific absorbed fraction‏‎ (1 revision)
  144. ICRP Publication 29‏‎ (1 revision)
  145. Surface contamination‏‎ (1 revision)
  146. ICRP Publication 35‏‎ (1 revision)
  147. ICRP Publication 5‏‎ (1 revision)
  148. Dose-threshold hypothesis‏‎ (1 revision)
  149. Translocation‏‎ (1 revision)
  150. Multistage carcinogenesis model‏‎ (1 revision)
  151. ICRP Publication 64‏‎ (1 revision)
  152. ICRP Publication 79‏‎ (1 revision)
  153. Phantom‏‎ (1 revision)
  154. 1956 Recommendations‏‎ (1 revision)
  155. Activation‏‎ (1 revision)
  156. Ras‏‎ (1 revision)
  157. ICRP Publication 1‏‎ (1 revision)
  158. Baseline disease rates‏‎ (1 revision)
  159. Reference phantom‏‎ (1 revision)
  160. ICRP Publication 110‏‎ (1 revision)
  161. Breakpoint cluster region/abelson‏‎ (1 revision)
  162. ICRP Publication 90‏‎ (1 revision)
  163. ICRP Publication 126‏‎ (1 revision)
  164. ICRP Publication 140‏‎ (1 revision)
  165. Slice‏‎ (1 revision)
  166. ICRP Publication 155‏‎ (1 revision)
  167. ICRP Publication 3‏‎ (1 revision)
  168. ICRP Publication 36‏‎ (1 revision)
  169. Dicentric chromosome‏‎ (1 revision)
  170. Threshold level‏‎ (1 revision)
  171. ICRP Publication 50‏‎ (1 revision)
  172. Dose and dose-rate effectiveness factor‏‎ (1 revision)
  173. ICRP Publication 65‏‎ (1 revision)
  174. ICRP Publication 8‏‎ (1 revision)
  175. Organ at risk‏‎ (1 revision)
  176. 1959 Decisions‏‎ (1 revision)
  177. Principles of protection‏‎ (1 revision)
  178. Radiation-induced second cancer‏‎ (1 revision)
  179. Hereditary effect‏‎ (1 revision)
  180. Rb‏‎ (1 revision)
  181. ICRP Publication 10‏‎ (1 revision)
  182. Reference value‏‎ (1 revision)
  183. ICRP Publication 111‏‎ (1 revision)
  184. ICRP Publication 91‏‎ (1 revision)
  185. ICRP Publication 127‏‎ (1 revision)
  186. ICRP Publication 141‏‎ (1 revision)
  187. Informed consent‏‎ (1 revision)
  188. ICRP Publication 16‏‎ (1 revision)
  189. Spongiosa‏‎ (1 revision)
  190. ICRP Publication 30‏‎ (1 revision)
  191. Dental and maxillofacial imaging‏‎ (1 revision)
  192. ICRP Publication 37‏‎ (1 revision)
  193. Marrow cellularity‏‎ (1 revision)
  194. ICRP Publication 51‏‎ (1 revision)
  195. Multitarget equation‏‎ (1 revision)
  196. ICRP Publication 66‏‎ (1 revision)
  197. ICRP Publication 80‏‎ (1 revision)
  198. Pilomatricoma‏‎ (1 revision)
  199. Active detection system‏‎ (1 revision)
  200. Radiation-induced secondary malignancy‏‎ (1 revision)
  201. Radiological attack‏‎ (1 revision)
  202. Reactive oxygen species‏‎ (1 revision)
  203. ICRP Publication 100‏‎ (1 revision)
  204. Reference worker‏‎ (1 revision)
  205. ICRP Publication 112‏‎ (1 revision)
  206. ICRP Publication 92‏‎ (1 revision)
  207. ICRP Publication 93‏‎ (1 revision)
  208. ICRP Publication 128‏‎ (1 revision)
  209. ICRU 4-element tissue‏‎ (1 revision)
  210. ICRP Publication 142‏‎ (1 revision)
  211. Compartment‏‎ (1 revision)
  212. ICRP Publication 17‏‎ (1 revision)
  213. Count median diameter‏‎ (1 revision)
  214. ICRP Publication 30 (Index)‏‎ (1 revision)
  215. System of radiological protection‏‎ (1 revision)
  216. ICRP Publication 38‏‎ (1 revision)
  217. Time-resolved computed tomography‏‎ (1 revision)
  218. ICRP Publication 52‏‎ (1 revision)
  219. Dose commitment‏‎ (1 revision)
  220. Mutation component‏‎ (1 revision)
  221. ICRP Publication 67‏‎ (1 revision)
  222. Doubling dose‏‎ (1 revision)
  223. Waste management‏‎ (1 revision)
  224. Normal tissue complication probability‏‎ (1 revision)
  225. ICRP Publication 81‏‎ (1 revision)
  226. Evacuation‏‎ (1 revision)
  227. Exposure index‏‎ (1 revision)
  228. AML/eto‏‎ (1 revision)
  229. Frequent flyer‏‎ (1 revision)
  230. Radiological controlled area‏‎ (1 revision)
  231. Attributable risk‏‎ (1 revision)
  232. ICRP Publication 101‏‎ (1 revision)
  233. Best available techniques‏‎ (1 revision)
  234. Referrer‏‎ (1 revision)
  235. ICRP Publication 113‏‎ (1 revision)
  236. Bronchiolar region‏‎ (1 revision)
  237. ICRP Publication 94‏‎ (1 revision)
  238. ICRP Publication 129‏‎ (1 revision)
  239. ICRU sphere‏‎ (1 revision)
  240. ICRP Publication 143‏‎ (1 revision)
  241. Compartment (environmental)‏‎ (1 revision)
  242. ICRP Publication 18‏‎ (1 revision)
  243. Cross section‏‎ (1 revision)
  244. ICRP Publication 30 (Part 1)‏‎ (1 revision)
  245. Deposition‏‎ (1 revision)
  246. ICRP Publication 39‏‎ (1 revision)
  247. Digital breast tomosynthesis‏‎ (1 revision)
  248. ICRP Publication 53‏‎ (1 revision)
  249. Treatment preparation in radiotherapy‏‎ (1 revision)
  250. ICRP Publication 68‏‎ (1 revision)
  251. Notification value‏‎ (1 revision)
  252. ICRP Publication 82‏‎ (1 revision)
  253. Other (systemic) tissues‏‎ (1 revision)
  254. Excess absolute risk‏‎ (1 revision)
  255. Exposure pathway‏‎ (1 revision)
  256. Functional subunits‏‎ (1 revision)
  257. Activity median aerodynamic diameter‏‎ (1 revision)
  258. Ground-level enhancement‏‎ (1 revision)
  259. ICRP Publication 101a‏‎ (1 revision)
  260. Region‏‎ (1 revision)
  261. ICRP Publication 114‏‎ (1 revision)
  262. ICRP Publication 95‏‎ (1 revision)
  263. ICRP Publication 13‏‎ (1 revision)
  264. Clinical audit‏‎ (1 revision)
  265. Sealed source‏‎ (1 revision)
  266. ICRP Publication 144‏‎ (1 revision)
  267. Solar flare‏‎ (1 revision)
  268. ICRP Publication 19‏‎ (1 revision)
  269. ICRP Publication 30 (Part 2)‏‎ (1 revision)
  270. Linear dose response‏‎ (1 revision)
  271. ICRP Publication 4‏‎ (1 revision)
  272. Mean glandular dose‏‎ (1 revision)
  273. ICRP Publication 54‏‎ (1 revision)
  274. Trophic level‏‎ (1 revision)
  275. ICRP Publication 69‏‎ (1 revision)
  276. Nuclear medicine‏‎ (1 revision)
  277. ICRP Publication 83‏‎ (1 revision)
  278. Pooled analysis‏‎ (1 revision)
  279. Radiation risk‏‎ (1 revision)
  280. Homologous recombination‏‎ (1 revision)
  281. Authorised discharge‏‎ (1 revision)
  282. ICRP Publication 101b‏‎ (1 revision)
  283. Regional diagnostic reference levels‏‎ (1 revision)
  284. ICRP Publication 115‏‎ (1 revision)
  285. Reversibility‏‎ (2 revisions)
  286. Clonogenic cells‏‎ (2 revisions)
  287. In vivo radiobioassay‏‎ (2 revisions)
  288. Solar particle event‏‎ (2 revisions)
  289. Curie‏‎ (2 revisions)
  290. Effect Dose 50‏‎ (2 revisions)
  291. Worker‏‎ (2 revisions)
  292. Nuclear track detectors‏‎ (2 revisions)
  293. Endogeneous excretion‏‎ (2 revisions)
  294. Exposure to Radon at Home‏‎ (2 revisions)
  295. GATA binding protein 2‏‎ (2 revisions)
  296. Radiation safety officer‏‎ (2 revisions)
  297. Radioresponsiveness‏‎ (2 revisions)
  298. Hormones‏‎ (2 revisions)
  299. Authorization‏‎ (2 revisions)
  300. Recovery responder‏‎ (2 revisions)
  301. Cardiac arrhythmias‏‎ (2 revisions)
  302. Right to know‏‎ (2 revisions)
  303. Clonogenic survival‏‎ (2 revisions)
  304. Incidence‏‎ (2 revisions)
  305. Solar wind‏‎ (2 revisions)
  306. Cytokines‏‎ (2 revisions)
  307. Target tissue‏‎ (2 revisions)
  308. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  309. Working level‏‎ (2 revisions)
  310. OLINDA/EXM‏‎ (2 revisions)
  311. Particle radiance‏‎ (2 revisions)
  312. Protection strategy‏‎ (2 revisions)
  313. Acute radiation syndrome‏‎ (2 revisions)
  314. Radiation source‏‎ (2 revisions)
  315. Radiosensitiser‏‎ (2 revisions)
  316. Hounsfield unit‏‎ (2 revisions)
  317. Authorized limit‏‎ (2 revisions)
  318. Rehabilitation of living conditions‏‎ (2 revisions)
  319. ICRP Publication 118‏‎ (2 revisions)
  320. Cardiac valve diseases‏‎ (2 revisions)
  321. Rigidity‏‎ (2 revisions)
  322. Security‏‎ (2 revisions)
  323. Incident‏‎ (2 revisions)
  324. Intermediate level waste‏‎ (2 revisions)
  325. Stenosis‏‎ (2 revisions)
  326. Local DRL‏‎ (2 revisions)
  327. Disposal‏‎ (2 revisions)
  328. Tolerability‏‎ (2 revisions)
  329. Medical exposure‏‎ (2 revisions)
  330. Dose criteria‏‎ (2 revisions)
  331. Naturally occurring radioactive material‏‎ (2 revisions)
  332. Working level month‏‎ (2 revisions)
  333. Environmental exposure‏‎ (2 revisions)
  334. Exempt waste‏‎ (2 revisions)
  335. Adaptive response‏‎ (2 revisions)
  336. Alveolar-interstitial region‏‎ (2 revisions)
  337. Radiosensitivity, cellular‏‎ (2 revisions)
  338. Autoimmune disease‏‎ (2 revisions)
  339. Co-expertise‏‎ (2 revisions)
  340. Inclusiveness‏‎ (2 revisions)
  341. Connective tissue‏‎ (2 revisions)
  342. Source-related‏‎ (2 revisions)
  343. Internal conversion electron‏‎ (2 revisions)
  344. DRL process‏‎ (2 revisions)
  345. LD 50/30‏‎ (2 revisions)
  346. Telangiectasia‏‎ (2 revisions)
  347. Member of the public‏‎ (2 revisions)
  348. Unattached fraction‏‎ (2 revisions)
  349. Necrosis‏‎ (2 revisions)
  350. Environmental radiation protection‏‎ (2 revisions)
  351. Patient entrance reference point‏‎ (2 revisions)
  352. Exemption level‏‎ (2 revisions)
  353. Potential recoverability correction factor‏‎ (2 revisions)
  354. Protective action guide‏‎ (2 revisions)
  355. Radiation worker‏‎ (2 revisions)
  356. Cardioverter-defibrillator‏‎ (2 revisions)
  357. Self-help protection‏‎ (2 revisions)
  358. Individual-related‏‎ (2 revisions)
  359. Consequential late effects‏‎ (2 revisions)
  360. Storage‏‎ (2 revisions)
  361. Track structure‏‎ (2 revisions)
  362. Mendelian diseases‏‎ (2 revisions)
  363. Neurological syndrome‏‎ (2 revisions)
  364. Effective dose equivalent‏‎ (2 revisions)
  365. Occupational exposure‏‎ (2 revisions)
  366. Peak skin dose‏‎ (2 revisions)
  367. Existing exposure situation‏‎ (2 revisions)
  368. Gastroschisis‏‎ (2 revisions)
  369. Radioactive dispersion device‏‎ (2 revisions)
  370. Angiogenesis‏‎ (2 revisions)
  371. Radon: Units of Measure‏‎ (2 revisions)
  372. Hyperbaric oxygen‏‎ (2 revisions)
  373. Reference air kerma‏‎ (2 revisions)
  374. Bioturbation‏‎ (2 revisions)
  375. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  376. Cohort study‏‎ (2 revisions)
  377. Individual decontamination‏‎ (2 revisions)
  378. DRL value‏‎ (2 revisions)
  379. Subcutaneous tissue‏‎ (2 revisions)
  380. Low dose rate‏‎ (2 revisions)
  381. Transfer compartment‏‎ (2 revisions)
  382. Mitigation‏‎ (2 revisions)
  383. Upper reference levels‏‎ (2 revisions)
  384. Neurovascular syndrome‏‎ (2 revisions)
  385. Epithelium‏‎ (2 revisions)
  386. Pelagic‏‎ (2 revisions)
  387. Practical radiological protection culture‏‎ (2 revisions)
  388. Acceptance test‏‎ (2 revisions)
  389. Gastrulation‏‎ (2 revisions)
  390. Radioactive source‏‎ (2 revisions)
  391. Habitual mouth breather‏‎ (2 revisions)
  392. Annihilation photons‏‎ (2 revisions)
  393. Hyperfractionation‏‎ (2 revisions)
  394. Bone marrow‏‎ (2 revisions)
  395. Risk coefficient‏‎ (2 revisions)
  396. Individual monitoring‏‎ (2 revisions)
  397. Containment‏‎ (2 revisions)
  398. Source term‏‎ (2 revisions)
  399. Latent time/period or latency interval‏‎ (2 revisions)
  400. Low level waste‏‎ (2 revisions)
  401. Dose-length product‏‎ (2 revisions)
  402. Equieffective dose‏‎ (2 revisions)
  403. Expanded and aligned radiation field‏‎ (2 revisions)
  404. Qualified expert‏‎ (2 revisions)
  405. Adventitious‏‎ (2 revisions)
  406. Radioactive substance‏‎ (2 revisions)
  407. Habitual nose breather‏‎ (2 revisions)
  408. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  409. Background dose (rate)‏‎ (2 revisions)
  410. Reference biokinetic model‏‎ (2 revisions)
  411. Relocation‏‎ (2 revisions)
  412. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  413. Intervention Level‏‎ (2 revisions)
  414. Substantial radiation dose level‏‎ (2 revisions)
  415. Detriment‏‎ (2 revisions)
  416. Dose-rate effect‏‎ (2 revisions)
  417. Transfer rate‏‎ (2 revisions)
  418. Multi-detector computed tomography‏‎ (2 revisions)
  419. Electron-capture decay‏‎ (2 revisions)
  420. Percutaneous coronary intervention‏‎ (2 revisions)
  421. Prevailing circumstances‏‎ (2 revisions)
  422. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  423. Radon Recommendations for Authorities‏‎ (2 revisions)
  424. Hypoplasia‏‎ (2 revisions)
  425. Backscatter detection system‏‎ (2 revisions)
  426. Reference individual‏‎ (2 revisions)
  427. Bradycardia‏‎ (2 revisions)
  428. Remedial action‏‎ (2 revisions)
  429. Risk of Exposure to Radon‏‎ (2 revisions)
  430. Coronary heart disease‏‎ (2 revisions)
  431. South Atlantic anomaly‏‎ (2 revisions)
  432. Interventional procedure‏‎ (2 revisions)
  433. Decay constant‏‎ (2 revisions)
  434. Lymphatic system‏‎ (2 revisions)
  435. Transforming growth factor‏‎ (2 revisions)
  436. Dose of record Hp (10)‏‎ (2 revisions)
  437. Electrophysiology‏‎ (2 revisions)
  438. Pericarditis‏‎ (2 revisions)
  439. Principle of application of dose limits‏‎ (2 revisions)
  440. Accreditation‏‎ (2 revisions)
  441. Genomic integrity‏‎ (2 revisions)
  442. Radioactivity‏‎ (2 revisions)
  443. Hazard‏‎ (2 revisions)
  444. Radon Recommendations for Workplaces‏‎ (2 revisions)
  445. Reference level‏‎ (2 revisions)
  446. Bragg peak‏‎ (2 revisions)
  447. Remediation‏‎ (2 revisions)
  448. Chronic exposure‏‎ (2 revisions)
  449. Routine monitoring‏‎ (2 revisions)
  450. ICRPædia Guide to Radon‏‎ (2 revisions)
  451. Colony‏‎ (2 revisions)
  452. Cosmic Radiation in Aviation‏‎ (2 revisions)
  453. Special (non-routine) monitoring‏‎ (2 revisions)
  454. Decommissioning‏‎ (2 revisions)
  455. Lifetime risk‏‎ (2 revisions)
  456. Macrophage colony stimulating factor‏‎ (2 revisions)
  457. Dose-threshold‏‎ (2 revisions)
  458. Multiplicative risk projection model‏‎ (2 revisions)
  459. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  460. Action Level‏‎ (2 revisions)
  461. Health Surveillance‏‎ (2 revisions)
  462. Basal cell‏‎ (2 revisions)
  463. Branching fraction‏‎ (2 revisions)
  464. Repopulation‏‎ (2 revisions)
  465. Class SR-0 gases‏‎ (2 revisions)
  466. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  467. Decontamination‏‎ (2 revisions)
  468. Diastasis‏‎ (2 revisions)
  469. Threshold dose for tissue reactions‏‎ (2 revisions)
  470. Magnetosphere‏‎ (2 revisions)
  471. Dose per unit intake coefficient‏‎ (2 revisions)
  472. Emergency‏‎ (2 revisions)
  473. Exposure, external or internal‏‎ (2 revisions)
  474. Graft vs host disease‏‎ (2 revisions)
  475. Air-kerma, incident‏‎ (2 revisions)
  476. Radiographer‏‎ (2 revisions)
  477. Heliosphere‏‎ (2 revisions)
  478. Representative organism (non-human biota)‏‎ (2 revisions)
  479. Class SR-1 gases‏‎ (2 revisions)
  480. Safety‏‎ (2 revisions)
  481. Committed effective dose‏‎ (2 revisions)
  482. Cost-benefit analysis‏‎ (2 revisions)
  483. Specific effective energy‏‎ (2 revisions)
  484. Decontamination factor‏‎ (2 revisions)
  485. Limitation of dose‏‎ (2 revisions)
  486. Transmission detection system‏‎ (2 revisions)
  487. Multistage tumorigenesis‏‎ (2 revisions)
  488. Dose rate‏‎ (2 revisions)
  489. Non-sphericity parameter‏‎ (2 revisions)
  490. Emergency exposure situation‏‎ (2 revisions)
  491. Erythropoietin‏‎ (2 revisions)
  492. Pharynx‏‎ (2 revisions)
  493. Exposure (in the context of inhalation)‏‎ (2 revisions)
  494. Fractionation and dose delivery patterns‏‎ (2 revisions)
  495. Broad beam therapy irradiation technique‏‎ (2 revisions)
  496. Representative person‏‎ (2 revisions)
  497. Class SR-2 gases‏‎ (2 revisions)
  498. Safety case‏‎ (2 revisions)
  499. Committed equivalent dose‏‎ (2 revisions)
  500. Slow repair‏‎ (2 revisions)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)